NCT02154399View on ClinicalTrials.gov

EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

September 30, 2007

Study Completion Date

April 30, 2014

Conditions
Stage IA Non-Small Cell Lung CarcinomaStage IB Non-Small Cell Lung CarcinomaStage IIA Non-Small Cell Lung CarcinomaStage IIB Non-Small Cell Lung CarcinomaStage IIIA Non-Small Cell Lung CancerStage IIIB Non-Small Cell Lung Cancer
Interventions
DRUG

EF5

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery/thoracotomy

OTHER

Tissue Oxygen Measurement

Undergo tumor hypoxia measurement

Trial Locations (2)

27705

Durham Veterans Affairs Medical Center, Durham

27710

Duke University Medical Center, Durham

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT02154399 - EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung Cancer | Biotech Hunter | Biotech Hunter